762 related articles for article (PubMed ID: 18060931)
1. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
Jneid H; Moukarbel GV; Dawson B; Hajjar RJ; Francis GS
Am J Med; 2007 Dec; 120(12):1090.e1-8. PubMed ID: 18060931
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
3. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
[No Abstract] [Full Text] [Related]
4. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
Jorde UP
Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
[TBL] [Abstract][Full Text] [Related]
5. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
Ghanem FA; Movahed A
Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
[TBL] [Abstract][Full Text] [Related]
6. [Hyperkalemia, heart failure and reduced renal function].
Bugge JF
Tidsskr Nor Laegeforen; 2010 Jul; 130(13):1354-5. PubMed ID: 20596118
[No Abstract] [Full Text] [Related]
7. Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
Norgard NB; Stark JE
Pharmacotherapy; 2008 Jul; 28(7):920-31. PubMed ID: 18576907
[TBL] [Abstract][Full Text] [Related]
8. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
Azadpour M; Lamas GA
Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
Kubota T; Takeshita A
Nihon Rinsho; 2003 May; 61(5):801-6. PubMed ID: 12755006
[TBL] [Abstract][Full Text] [Related]
10. Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
Hennekens CH; Kowalczykowski M; Hollar D
J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):149-52. PubMed ID: 16891293
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
Bauersachs J; Fraccarollo D
Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
[TBL] [Abstract][Full Text] [Related]
12. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome.
Gotsman I; Rubonivich S; Azaz-Livshits T
Isr Med Assoc J; 2008 Mar; 10(3):214-8. PubMed ID: 18494235
[TBL] [Abstract][Full Text] [Related]
13. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
Phillips CO; Kashani A; Ko DK; Francis G; Krumholz HM
Arch Intern Med; 2007 Oct; 167(18):1930-6. PubMed ID: 17923591
[TBL] [Abstract][Full Text] [Related]
14. Reassessing guidelines for heart failure.
Drexler H; Wollert KC
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S28-33. PubMed ID: 15526240
[TBL] [Abstract][Full Text] [Related]
15. Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure.
Khattar RS
Minerva Cardioangiol; 2003 Apr; 51(2):143-54. PubMed ID: 12783070
[TBL] [Abstract][Full Text] [Related]
16. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation.
Jennings DL; Taber DJ
Ann Pharmacother; 2008 Jan; 42(1):116-20. PubMed ID: 18094340
[TBL] [Abstract][Full Text] [Related]
17. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
Makkar KM; Sanoski CA; Spinler SA
Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
Tokmakova M; Solomon SD
Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
[TBL] [Abstract][Full Text] [Related]
19. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
Dulin BR; Krum H
Curr Opin Cardiol; 2006 Jul; 21(4):393-9. PubMed ID: 16755210
[TBL] [Abstract][Full Text] [Related]
20. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
